about
Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance PatternsWhat is healthcare-associated pneumonia and how is it managed?Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantationImpact of an Educational Program to Reduce Healthcare Resources in Community-Acquired Pneumonia: The EDUCAP Randomized Controlled TrialManagement of community-acquired pneumonia in older adults.Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease.Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain.Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniquesRainfall is a risk factor for sporadic cases of Legionella pneumophila pneumonia.The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial.Increase in bloodstream infection due to vancomycin-susceptible Enterococcus faecium in cancer patients: risk factors, molecular epidemiology and outcomes.Effect of statin use on outcomes of adults with candidemia.Molecular epidemiology of nontypeable Haemophilus influenzae causing community-acquired pneumonia in adults.Causes of death in a contemporary cohort of patients with invasive aspergillosisEffect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trialBloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center.Fungal postoperative spondylodiscitis due to Scedosporium prolificans.Statins for community-acquired pneumonia: current state of the science.An update on Legionella.Peripheral facial palsy after varicella. Report of two cases and review of the literature.Community-acquired Legionella pneumophila pneumonia: a single-center experience with 214 hospitalized sporadic cases over 15 years.Clinical features, etiology, and outcomes of community-acquired pneumonia in patients with diabetes mellitus.Advances in antibiotic therapy for community-acquired pneumonia.Pathogenesis of invasive fungal infections.Prediction of prognosis by markers in community-acquired pneumonia.Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.Biomarkers for predicting short-term mortality in community-acquired pneumonia: A systematic review and meta-analysis.A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains.Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia.Empirical treatment of adults with hospital-acquired pneumonia: lights and shadows of the 2016 Clinical Practice ATS/IDSA Guidelines.Comments on practice guidelines for the diagnosis and management of aspergillosis made by the IDSA in 2016.Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia.Breakthrough candidaemia in the era of broad-spectrum antifungal therapies.Impact of pre-hospital antibiotic use on community-acquired pneumonia.PET/CT added to Duke criteria facilitates diagnosis and monitoring of long-term suppressive therapy of prosthetic endocarditis.Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis.Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia.Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients.[Invasive yeast infections in severely burned patients].
P50
Q28069467-81D3F083-D246-4090-853E-FDB2E6C17B89Q28271360-86B85613-9CE7-4C43-B8B6-12E644063B00Q28293483-C002A0BF-95FA-4F0B-8051-8125F9283ACBQ28550197-E9E69F88-E52C-4851-ACB8-BB63E2C4C1B4Q33810591-658AF8D8-F3EF-41F6-9E19-AAC486444FD9Q34105094-E78DBD34-7D1F-4E8B-A9D1-E6D0DD7F666AQ34281346-2E9DAE7F-02A2-43A9-8E95-39964BDBA8A4Q34658291-A9422353-DF74-4D88-B837-4EA4128C9774Q34683959-269D8FB1-3944-4D7C-B670-675967B81B6FQ34903761-926DA4B0-1450-4152-BB18-377421C2A854Q34999291-BF2D0326-3E9B-48CE-B2D9-8F1897D7E3BFQ35025431-3BF37A81-98CD-4D79-92C4-0A098E8FBE50Q35070330-1AD23D6E-4597-4F63-B32D-C2CACF836F36Q35213770-B057D49F-ACAE-489F-8B07-EB6C5CF9AE1CQ35559463-E7C46AAE-B6DA-4773-ADFC-C1A6249B358EQ36247827-2ADC3B97-9BE5-425F-97B8-1BDA3F578C03Q37485284-2C4BDBDF-52E5-4659-87EA-5F13A9B5CE4AQ37639928-2D4BA64D-4F9B-4A5E-A424-1B5BAB65289CQ37669060-758A5042-D3EF-4F98-8319-D45375F19867Q37688601-E3F6666B-B68E-41E5-B91F-53CBC8433A1CQ37696804-CCC1238F-D9A8-46B6-9179-679D6B91D7D7Q37726612-D63F0B71-CC45-42C9-A433-087E9911A4ACQ38082927-CB133CC8-ADD2-4749-ACB8-5265C45A3ACEQ38085475-0D7A2503-4E93-43A2-ACED-8334D43001DCQ38140013-6ACD2F97-BE3E-43C3-BF23-F861C2144207Q38468980-50D3E323-35D5-4F29-BCCE-C422164CF4BCQ38700020-861452B4-5F4B-4DDC-AC84-96DAC3221264Q39029924-E170DE3E-EE68-45F4-84F6-52F4777A7802Q39231468-9C376A19-3407-41E4-B5FA-1FDF85DED583Q40062328-3BA6E49A-5CE6-4E36-A253-F26ED92F0A77Q40062333-FB92CE63-EE96-461F-BA1D-C62E07E671C2Q40102140-56B6D763-3618-4579-8661-0DB72A6A4992Q40135487-673A6891-CD46-4320-8654-5BE8319F6D82Q40211408-0C478B64-FF95-4493-9A7B-08074DF2AC92Q40292791-7B6F0D05-372F-46DF-BBAF-0749A54B443AQ40305264-530F8985-0B16-42B2-AEA8-FADEBE53596AQ40369913-2609587A-CB7D-4E72-85C3-D5EC0641315AQ40562962-98B96A27-4DF0-4E0C-B7D2-EFE943171B1EQ40613102-7E299029-A762-4C3C-93EB-93507915FB2BQ40619790-C233DCFD-3267-4ACC-A53D-5B1A63414AF2
P50
description
researcher ORCID ID = 0000-0002-8915-0683
@en
wetenschapper
@nl
name
Carolina Garcia-Vidal
@ast
Carolina Garcia-Vidal
@en
Carolina Garcia-Vidal
@es
Carolina Garcia-Vidal
@nl
type
label
Carolina Garcia-Vidal
@ast
Carolina Garcia-Vidal
@en
Carolina Garcia-Vidal
@es
Carolina Garcia-Vidal
@nl
prefLabel
Carolina Garcia-Vidal
@ast
Carolina Garcia-Vidal
@en
Carolina Garcia-Vidal
@es
Carolina Garcia-Vidal
@nl
P1153
56677579000
P21
P31
P496
0000-0002-8915-0683